Olwam Plaatjie, nineteen years old, watched her family shrink under the weight of HIV—the pills, the clinic visits, the slow unraveling of people she loved—and decided she wouldn't let that happen to her. Three years ago, she began taking preventive HIV medications, becoming one of thousands of South Africans to enroll in clinical trials for lenacapavir, a drug that would transform how prevention works in the country bearing the world's heaviest burden of HIV.
In June 2026, South Africa became one of the first nations to roll out lenacapavir, a twice-yearly injectable that fundamentally changes the calculus of HIV prevention. Unlike daily oral pills—which demand unwavering adherence and carry side effects that can feel like a constant reminder of risk—lenacapavir offers protection with just two shots a year. A crucial study conducted in Johannesburg showed 100% effectiveness in preventing HIV infection, a result so definitive that Dr. Nkosi Ndlovu, senior clinician at the research institute Wits RHI, called it "groundbreaking." Even as young participants like Plaatjie endured night sweats and other side effects, they stayed the course, understanding what was at stake.
President Cyril Ramaphosa, speaking at the launch in Secunda to a stadium crowd, named lenacapavir a "turning point" for a country where over eight million people live with HIV and new infections persist at 140,000 to 170,000 each year. The government has secured doses for approximately 456,000 people for a year, funded by a $29 million grant from the Global Fund. Ramaphosa committed to reaching three million South Africans over the next three years, though implementation details remain sparse. After the initial year, Health Minister Aaron Motsoaledi signaled that South Africa intends to fund the program independently, with donor support.
The optimism is grounded. Leila Mansoor, a senior scientist at the University of KwaZulu-Natal's Center for the AIDS Program of Research in South Africa, sees real potential: "If South Africa can deliver it equitably and at scale, it could make a meaningful contribution to reducing new HIV infections." Yet beneath the official celebration sits a tension that health advocates refuse to ignore.
South Africa's scientific infrastructure was essential to lenacapavir's development. Its researchers ran the trials that proved efficacy. Its clinics hosted the studies. Its communities participated in the research that made the breakthrough possible. And now, as the drug rolls out globally, some South African voices question whether their nation receives its due. Tian Johnson, health strategist for the Johannesburg-based African Alliance, articulated the frustration plainly: "Our communities participated in the research, our clinics hosted the trials and our scientists helped produce the data. Yet we are still waiting for Gilead to determine how much of the product we receive, when it arrives and how quickly access can expand."
There is a pathway forward. Gilead Sciences, the drug's developer, committed to granting a voluntary manufacturing license to a South African company, which would enable cheaper generics priced at $40 per person annually—a dramatic drop from the original $28,000. Some civil society organizations argue that at least two million doses per year are necessary to meaningfully bend the curve on infections. The conversations about scale, speed, and equity are just beginning, but South Africa's moment has arrived.